EUVIMEDEUVIMED entdecken
Crossref

Advancing the preclinical development of ONR-001, a first-in-class TET2 activator for the treatment of cancer

D. Aguilar, I. Puig, O. Arqués, I. Chicote, L. Cabellos, S. Farran, C. Díaz, E. Monreal, H.G. Palmer

European Journal of Cancer · 2026-11 · 248 · 117734

DOI: 10.1016/j.ejca.2026.117734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von D. Aguilar und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Aguilar, D., Puig, I., Arqués, O., Chicote, I., Cabellos, L., Farran, S., Díaz, C., Monreal, E., & Palmer, H. (2026). Advancing the preclinical development of ONR-001, a first-in-class TET2 activator for the treatment of cancer. European Journal of Cancer, 248, 117734. https://doi.org/10.1016/j.ejca.2026.117734

Vancouver

Aguilar D, Puig I, Arqués O, Chicote I, Cabellos L, Farran S, et al. Advancing the preclinical development of ONR-001, a first-in-class TET2 activator for the treatment of cancer. European Journal of Cancer. 2026;248:117734. doi:10.1016/j.ejca.2026.117734

BibTeX
@article{Aguilar2026,
  author = {Aguilar, D. and Puig, I. and Arqués, O. and Chicote, I. and Cabellos, L. and Farran, S. and Díaz, C. and Monreal, E. and Palmer, H.G.},
  title = {Advancing the preclinical development of ONR-001, a first-in-class TET2 activator for the treatment of cancer},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117734},
  doi = {10.1016/j.ejca.2026.117734}
}
Kostenlos starten →